Loading…
Loading…
IVF does not currently pay a dividend.
Sell-side consensus EPS, revenue estimates, YoY growth, forward P/E, and per-year analyst coverage — for any covered stock.
Click below to see what's inside, then upgrade to unlock for this and 80,000+ other tickers.
A year-by-year projected price path from the sell-side EPS consensus, with an editable target P/E and the implied annual return from today's price.
Click below to see what's inside, then upgrade to unlock for IVF and 80,000+ other tickers.
See price against where its own fundamentals say it should trade — the shaded gap is the discount or premium, across five valuation lenses.
Click below to see what's inside, then upgrade to unlock for IVF and 80,000+ other tickers.
See exactly how IVF's revenue becomes profit — a Sankey that traces revenue (and its reported segments) through gross profit, operating expenses, and net profit, with the year-over-year change on every line.
The same diagram the Chart Builder draws, right on the Summary tab. Upgrade to unlock it for IVF and 80,000+ other tickers.
INVO Fertility, Inc. is a profitable enterprise primarily focused on delivering fertility services. Beyond this core business, the company actively develops clinical-stage therapies targeting oncology and autoimmune disorders. The firm was established on January 5, 2007, and its operations are based in Sarasota, Florida.
SARASOTA, Fla., Aug. 20, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) ("INVO Fertility" or the "Company"), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced that Gretchen Collins, M.D.
Shares of INVO Fertility Inc. (NASDAQ:IVF) are surging Monday afternoon after the healthcare fertility company reported second-quarter financial results that significantly outperformed Wall Street expectations on bottom-line earnings.
Q2 2026 revenue increased 17% as INVO advances organic growth and a disciplined acquisition strategy focused on established, profitable fertility practices Clinic platform was profitable on an Adjusted EBITDA basis before corporate operating and public company expenses SARASOTA, Fla., Aug. 17, 2026 (GLOBE NEWSWIRE) -- INVO Fertility, Inc. (Nasdaq: IVF) (“INVO Fertility” or the “Company”), a healthcare fertility company focused on the establishment, acquisition, and operation of fertility clinics and related businesses and technologies, today announced financial results for the second quarter ended June 30, 2026.
INVO Fertility Inc (NASDAQ:IVF) shares are surging Friday afternoon following a pair of key operational and regulatory milestones disclosed in a new SEC Form 8-K filing. Here's what investors need to know.
23% revenue growth, elimination of all Series C-2 Preferred Stock and warrant liabilities, and a strengthened balance sheet